Tetrahydrouridine + Decitabine

Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
20 patients (estimated)
Sponsors
EpiDestiny, Inc.
Tags
Cytidine Deaminase Inhibitor (CDAi)
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
2129
NCT Identifier
NCT07006025

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.